|
POLR1B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.83030000044937E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.84839999994857E-06 |
| Normal-vs-Stage2 |
3.288000E-02 |
| Normal-vs-Stage3 |
6.59509999945129E-08 |
| Normal-vs-Stage4 |
1.76630000003897E-06 |
| Stage1-vs-Stage2 |
1.191990E-01 |
| Stage1-vs-Stage3 |
1.219820E-01 |
| Stage1-vs-Stage4 |
2.042400E-01 |
| Stage2-vs-Stage3 |
1.466060E-02 |
| Stage2-vs-Stage4 |
3.840000E-02 |
| Stage3-vs-Stage4 |
9.302600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.24860000116911E-08 |
| Normal-vs-AfricanAmerican |
1.140360E-02 |
| Normal-vs-Asian |
2.816000E-03 |
| Caucasian-vs-AfricanAmerican |
3.265000E-01 |
| Caucasian-vs-Asian |
8.110200E-02 |
| AfricanAmerican-vs-Asian |
7.689000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.23989999998042E-07 |
| Normal-vs-Female |
1.00079999998393E-06 |
| Male-vs-Female |
2.383600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.97399999996217E-06 |
| Normal-vs-Age(41-60Yrs) |
2.07630000004233E-06 |
| Normal-vs-Age(61-80Yrs) |
2.3543999999931E-05 |
| Normal-vs-Age(81-100Yrs) |
3.536800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.835200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.101200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.423200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.175000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.276000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.591200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.551600E-02 |
| Classical-VS-Follicular |
9.576000E-01 |
| Classical-VS-Other |
2.093200E-01 |
| Classical-VS-Normal |
2.75270000005268E-06 |
| Tall-VS-Follicular |
1.265640E-01 |
| Tall-VS-Other |
7.204400E-01 |
| Tall-VS-Normal |
1.79338999999334E-05 |
| Follicular-VS-Other |
2.664600E-01 |
| Follicular-VS-Normal |
4.403300E-04 |
| Other-VS-Normal |
6.560100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.70763999999268E-05 |
| Normal-vs-N1 |
5.57060000350162E-08 |
| N0-vs-N1 |
2.635700E-02 |
|
|
